AXAFA – AFNET 5 Trial

 

Title

Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy (AXAFA)

This study is partially funded by the DZHK
 

Summary

AXAFA – AFNET 5 is an investigator-driven, prospective, parallel-group, randomised, open, blinded outcome assessment (PROBE), multi-centre trial to determine the optimal anticoagulation therapy for patients undergoing catheter ablation of atrial fibrillation.
Read more

Current Status

Patient enrolment is ongoing since 27.02.2015
319 patientes enrolled
39 sites open for recruitment
Status as of 29.06.2016, updates are carried out quarterly

Number of Patients

630

Participating Countries

Europe, USA

International Chief Investigator

Prof. Paulus Kirchhof, Birmingham, UK / Münster, Germany

Overall Responsibility

Sponsor: Kompetenznetz Vorhofflimmern e.V.  (AFNET e.V.), Münster, Germany  

Partners

 

Deutsches Zentrum für Herz-Kreislauf-Forschung e.V. (DZHK)

Financial Supporters:

Bristol-Myers Squibb

Pfizer

Flyer for investigators

Registration

EudraCT number: 2014-002442-45
ClinicalTrials.gov: NCT02227550
ISRCTN: ISRCTN87711003

Contact

Kompetenznetz Vorhofflimmern e.V.
Mendelstraße 11
48149 Münster, Germany
Phone: +49 251 9801340
Fax: +49 251 9801349 
Email: info@kompetenznetz-vorhofflimmern.de
http://www.kompetenznetz-vorhofflimmern.de